AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02492763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
Study NCT02492763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
Study NCT02492763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.
Study NCT02492763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
Study NCT02492763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
Study NCT02492763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
Study NCT01038843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VA106483
Description: Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above
Study NCT01038843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above
Study NCT02528981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Lactobacillus GR-1 and RC-14
Study NCT02528981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03236376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional sensorimotor therapy for the upper limb
Description: The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of sensory discrimination training and sensorimotor training.
Study NCT03236376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: additional motor therapy for the upper limb after stroke
Description: The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of cognitive-attention based training and motor training
Study NCT00512213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunonutrition for 5 days preoperative
Description: Impact vs Meritene
Study NCT00512213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard enteral nutrition for 5 days preoperative
Description: Impact vs Meritene
Study NCT02524782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-4166
Description: MEDI-4166 administered subcutaneously
Study NCT02524782 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT03481595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HealthLoop mobile application
Description: Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.
Study NCT01567540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg Sitagliptin daily for 15 weeks
Study NCT01147510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of low ICS and montelukast
Description: Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
Study NCT01147510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy of medium dose ICS
Description: Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
Study NCT02846506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
Study NCT02846506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Study NCT02846506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Study NCT02846506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Study NCT02292589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frontal Stimulation
Description: The patient will receive anodal tDCS on left dorsolateral prefrontal cortex with an intensity of 1.5 mA for 20 minutes.
Study NCT02292589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporal Stimulation
Description: The patient will receive anodal tDCS on left temporal cortex with an intensity of 1.5 mA for 20 minutes.
Study NCT02292589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Stimulation
Description: The patient will receive anodal tDCS over the occipital area for 30 seconds only and then it will be turned off without the patient's knowledge.
Study NCT00359320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy
Study NCT01295164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classic aberrometer and aberrometer AOVIS-1
Description: Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer.
Study NCT01295164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aberrometer AOVIS-I
Description: Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
Study NCT04207788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIP-REP
Description: HIP-REP programme is an add on to usual care which includes 5 add on individual activity-focused interventions that will be tailored to the need of elderly with hip fracture in a liaison with the health care professionals. Home visits and follow-up phone call will be a part of programme.
Study NCT04207788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The elderly in the control group will receive usual rehabilitation. with a focus on mobilization within 24 hours postoperative as an in-patient. In the municipality physiotherapy is offered twice a week for approximately 12 weeks postoperative focusing on neuromotor control over hip, activation and strengthening of muscles as well as increase mobility. When relevant, the elderly receives a home visit by an occupational therapist who assess ADL behaviours, the use of assistive devices and the environmental hazards, preparing and adapting the home environment to prevent falls.
Study NCT00692835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy (Mini Video Assisted Thyroidectomy)
Description: Immediate postoperative course of patients with Thyroidectomy
Study NCT00692835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy (Classic Thyroidectomy)
Description: Immediate postoperative course of patients with Thyroidectomy
Study NCT01413204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284 Low
Description: The patients will receive TA-7284-Low orally for 24 weeks.
Study NCT01413204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284 High
Description: The patients will receive TA-7284-High orally for 24 weeks.
Study NCT01413204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive Placebo orally for 24 weeks.
Study NCT00811915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml
Study NCT00811915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml
Study NCT01751620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ACCEPT
Description: The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.
Study NCT01751620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEALTH
Description: The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
Study NCT02497170 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education of goal setting and achievement
Description: Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
Study NCT02991872 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
Study NCT00521404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008 (humanized anti-DR5 antibody)
Description: CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
Study NCT00521404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine - 1000mg/meter sq
Study NCT02444767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13mg Bimatoprost Ocular Insert
Description: 13mg Bimatoprost Ocular Insert in each eye.
Study NCT00430404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative care (Intervention)
Description: Structured shared care with treatment protocol \& support
Study NCT00753181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Formula
Description: nutritional shake daily
Study NCT00753181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet
Description: usual dietary habits
Study NCT00753181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.
Description: nutritional shake, diabetes specific cereal and diabetes snack bar daily
Study NCT02740101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin (40 IU)
Study NCT02740101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo (40 IU)
Study NCT04424719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule :~(i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines).~(ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research.~* M0 : during the first medical oncology visit.~* At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120).~* At the diagnosis of metastasis.~* At each significant event during the metastatic disease (surgery, treatment response or progression).
Study NCT02607709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy in conjugation with nephroureterectomy
Description: Lymphadenectomy (intervention group only):~Lymphadenectomy performs in four fractions on the right side and two fractions on the left side according to Dissection template (Appendix 1). Renal hilar nodes are included in fraction 1 and 3, respectively.
Study NCT02607709 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nephroureterectomy without lymphadenectomy
Description: Removing the kidney, ureter and bladder cuff
Study NCT00882557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: intradialytic: 9 mg/kg during the last 30 minutes of dialysis
Study NCT00882557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: 6 mg/kg administered after a hemodialysis session
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Daily physical activity levels
Description: Objectively measured physical activity using activity monitors.
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test
Description: Assessment of functional exercise capacity.
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing
Description: Assessment of maximal exercise capacity.
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle Function
Description: Assessment of muscle force, muscle endurance and muscle fatigability
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function
Description: Assessment of whole-body plethysmography and spirometry.
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Body composition
Description: Assessment of bioelectrical impedance.
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HRQoL - SGRQ-I
Description: Assessment of Health-related quality of life by the Saint-George Respiratory questionnaire (SGRQ-I)
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Symptoms - UCSD/SOBQ
Description: Assessment of symptoms by the UCSD Short of breath questionnaire
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HRQoL - SF36
Description: Assessment of Health-related quality of life by the SF-36 questionnaire
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anxiety and depression
Description: Assessment of anxiety and depression by the Hospital Anxiety And Depression (HADS) Scale
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Symptoms - mMRC
Description: Assessment of symptoms by the modified Medical Research Council (mMRC) scale
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep quality
Description: Assessment of sleep by the Pitsburg Sleep Quality Index (PSQI)
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sleepiness
Description: Assessment of sleepiness by the Epworth Sleepiness Scale
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers and oxidative stress
Description: blood assessment of inflammatory markers: IL-2, IL-10, IL-6, IL-4 e IL-17A, TNF, Interferon-γ, CK and CRP.~Blood assessment of oxidative stress: TRAP, SH, SOD, CAT, PON 1, Gpx, MDA, NOx, FOX and AOPP.
Study NCT03400839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional performance tests
Description: Timed-up-and-go at usual pace (TUGu) and at a fast pace (TUGf), four-metre gait speed test (4MGS), sit-to-stand test using three protocols: 30 seconds (30sec-STS), one minute (1min-STS) and five-repetition (5rep-STS) and Short Physical Performance Balance (SPPB).
Study NCT03106311 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: assessment of beta subunit of human chorionic gonadotropin
Description: Vaginal washing fluid will be collected and sent for measurement of beta subunit of human chorionic gonadotropin
Study NCT03370900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing
Description: Participants either received 20 case testing with or without feedback
Study NCT02192411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1/4 dose lidocaine
Study NCT02192411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1/4 dose lidocaine
Study NCT00919321 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Description: One intramuscular injection
Study NCT02253446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam
Description: 20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
Study NCT02253446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
Study NCT03038880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab was administered via IVT injections as specified during the treatment period.
Study NCT03038880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab was administered via IVT injections as specified during the treatment period.
Study NCT03038880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
Study NCT02538978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Concentrate (aBMC)
Description: Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.~Device: SurgWerks-CLI Kit~Device: VXP System
Study NCT02538978 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control (diluted autologous peripheral blood)
Description: Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
Study NCT04075032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: Pomegranate extract consumption (900 mg/day) for 4 weeks
Study NCT04075032 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks
Study NCT02885025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli Sprout Extract
Description: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
Study NCT02885025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone nasal
Description: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.